Common Contracts
3 similar Agency Agreement contracts by Algernon Pharmaceuticals Inc.
AGENCY AGREEMENTAgency Agreement • January 21st, 2022 • Algernon Pharmaceuticals Inc. • Pharmaceutical preparations
The undersigned, Mackie Research Capital Corporation (the "Agent"), understands that Algernon Pharmaceuticals Inc. (the "Company") proposes to create, offer, issue and sell up to 17,143,000 special warrants of the Company ("Initial Special Warrants"), at a price of $0.35 per Special Warrant (the "Issue Price"), for aggregate gross proceeds of up to $6,000,050, or such other number of Initial Special Warrants as the Agent and the Company may agree (together with the Agent's Option (as defined below), the "Offering"), subject to the terms and conditions set out below. In addition, the Company has granted to the Agent an option (the "Agent's Option") exercisable, in whole or in part, at any time up to forty- eight (48) hours prior to the Time of Closing (as defined herein) to arrange for the sale of such number of additional special warrants of the Company as is equal to up to 15% of the number of Initial Special Warrants (the "Additional Special Warrants" and, together with the Initial S
AGENCY AGREEMENTAgency Agreement • December 2nd, 2020 • British Columbia
The undersigned, Mackie Research Capital Corporation, as lead agent and sole bookrunner (the “Lead Agent”) and Haywood Securities Inc. (together with the Lead Agent, the “Agents”), understand that BetterLife Pharma Inc. (the “Company”) proposes to create, offer, issue and sell up to 10,000,000 special warrants of the Company (“Initial Special Warrants”), at a price of $0.50 per Special Warrant (the “Issue Price”), for aggregate gross proceeds of up to $5,000,000, or such other number of Initial Special Warrants as the Agents and the Company may agree (together with the Agents’ Option (as defined below), the “Offering”), subject to the terms and conditions set out below. In addition, the Company has granted to the Agents an option (the “Agents’ Option”) exercisable, in whole or in part, at any time up to forty-eight (48) hours prior to the Time of Closing (as defined herein) to arrange for the sale of such number of additional special warrants of the Company as is equal to up to 15% of
AGENCY AGREEMENTAgency Agreement • September 10th, 2020
The undersigned, Stifel Nicolaus Canada Inc. (the “Lead Agent”), as lead agent and sole bookrunner (the “Lead Agent”), on behalf of itself and a syndicate of agents including Eight Capital (“Eight Capital”) (collectively, the “Agents”, and each individually, an “Agent”), understand that Voyager Digital Ltd. (the “Company”) proposes to create, offer, issue and sell up to 5,884,000 special warrants of the Company (the “Initial Special Warrants”) at a price of
